Mandate

Vinge advises EQT VII in its acquisition of Eton Group AB

December 30, 2015

Vinge advises EQT VII in its acquisition of Eton Group AB and its subsidiaries in Sweden, the US, Canada and the UK (together “Eton”) from Litorina IV and a number of minority shareholders. Founded in Gånghester, Sweden, in 1928, Eton is today a global premium men’s shirts brand, offering shirts and directly linked accessories. Eton primarily sells through department stores, complemented with five own brand stores and its own online store. Eton is still headquartered in Gånghester and has approximately 155 employees across the world. The transaction is conditional upon approval from competition authorities and is expected to close in early 2016.

Vinge’s team consists of partners Christina Kokko and Peter Sundgren together with associates Sofie Bjärtun and Adriana Berglund (both M&A), Karin Virding (IP), Parul Sharma and Linn Gustavsson (both CSR), Karin Isacsson (employment), Nicklas Thorgezon (IT), Jasmin Draszka-Ali, Ulrich Ziche and Maria Dahlin (agreements), Adam Sandberg (financing), Anna Lonergran (real property), Helena Höök (competition law) as well as project assistant Josefin Backlund. Partner Marcus Glader and associates Grant McKelvey and Johanna Bjurling advice in relation to merger filing.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026